Exploring Cannabis Pharmacology: Beyond THC and CBD

The landscape of cannabis pharmacology, once predominantly focused on tetrahydrocannabinol (THC), has dramatically expanded since the pioneering work of Raphael Mechoulam in the 1960s. This evolution reveals the complex interplay of cannabinoids like cannabidiol (CBD), which, alongside THC, contributes to the therapeutic versatility of cannabis. Recent research delves deeper, investigating the nuanced roles of lesser-known phytocannabinoids and the significant, yet often underestimated, impact of mono- and sesquiterpenoids found in cannabis flowers. These aromatic compounds enhance the plant's therapeutic profile, offering synergistic benefits that could revolutionize treatment approaches for pain, psychiatric disorders, cancer, and more. 

The concept of the "entourage effect" — the synergistic interaction between cannabinoids and terpenoids — highlights the intricate balance that enhances efficacy and therapeutic outcomes. Additionally, exploration into other cannabis plant parts uncovers unique compounds like the triterpenoid friedelin, canniprene, cannabisin, and notably, cannflavin A, each holding distinct pharmacological promises. 

Learn more about this paper and its findings here: 

Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads